Health Canada
www.hc-sc.gc.ca
Common menu bar links
Institutional links
About Health Canada
Access to Information Requests Completed - December 2010
This content was archived on June 24, 2013.
Archived Content
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)
If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.
Acronyms and Descriptions
- AER
- Adverse Reaction Report (Adverse Event)
- DIN
- Drug Identification Number
- NPN
- Natural Product Number
- SAE
- Serious adverse event
- SAP
- Special Authorization Program
Completed Requests
| Request # | Request text summary | Status of Completed Request |
|---|---|---|
| A-2008-00172 | Information with reference to the recent proposed 2008 Regulations Amending the Patented Medicines (Notice of Compliance) Regulations, Canada Gazette Part I, April 26, 2008. | Disclosed in part |
| A-2008-00774 | All documents related to Consumer Product Safety Branch's toy committee (question, enforcement about lead in coloured plastics substrate). Jan 1, 2007 to Nov 18, 2008. | Disclosed in part |
| A-2008-01048 | All information regarding the Scientific Advisory Committee on Respiratory and Allergy Therapies pertaining to the requirements for Abbreviated New Drug Submissions. Jan 1, 2007 to Feb 25, 2009. | Disclosed in part |
| A-2008-01088 | All records about incident and related investigation involving injured girl linked to ingestion of magnets from toy. Jul 8, 2008 to Mar 1, 2009. |
Disclosed in part |
| A-2008-01124 | Information regarding the products Aviane 21, Aviane 28, Portia 21, Portia 28 and Empressa. | Disclosed in part |
| A-2008-01149 | Briefing and meeting notes regarding meetings held between Health Canada officials on pharmaceutical and drug issues with trade associations Canada's Research-Based Pharmaceutical Companies (Rx & D) and BioteCanada or their member companies or their representatives. (Jul 1, 2008 to Mar 31, 2009). | Disclosed in part |
| A-2008-01159 | All outgoing e-mails sent by Janet Beauvais of Health Canada's Food Directorate between August 19 and September 22, 2008. | Disclosed in part |
| A-2009-00076 | Information regarding the product VFEND (voriconazole) by Pfizer Canada Inc. | Disclosed in part |
| A-2009-00144 | Information regarding the product Gen-Nifedipine XL 30 and 60 mg. | Disclosed in part |
| A-2009-00160 | All information regarding the hiring process for Electronic Maintenance Technologist. Dated December 06, 2006. Reference # SHC6J-006155-00289, Selection Process # 06-NHW-HE-EA 147. | Disclosed in part |
| A-2009-00313 | Information regarding adverse events for Acetaminophen from Health Canada Pharmacovigilance database related to the draft Acetaminophen labelling standard. | Disclosed in part |
| A-2009-00762 | Transcripts, minutes and/or notes taken during or after a September 16, 2009 conference call that Health Minister Leona Aglukkaq participated in with aboriginal leaders. | Disclosed in part |
| A-2009-00992 | Information regarding the products Portia 21, Portia 28 by Barr Laboratories Inc.. | Disclosed in part |
| A-2009-00995 | Information regarding the products Aviane 21, Aviane 28 by Barr Laboratories Inc. | Disclosed in part |
| A-2009-01003 | Information relating to oil and gas developments and operations in Alberta. Jan 1, 2008 to Nov 30, 2009. | All disclosed |
| A-2009-01020 | Any information Health Canada has relating to the diagnosis of mental illness generally and/or the confirmation or validation of a mental illness diagnosis. Oct 1, 2008 to Dec 31, 2008. | Disclosed in part |
| A-2009-01076 | Information regarding the product Crest Pro-Health Night Fluoride Toothpaste, NPN 80001224. | Disclosed in part |
| A-2009-01215 | Information regarding the product Renagel 800 mg Tabs by Genzyme Canada Inc. | Disclosed in part |
| A-2009-01252 | Question Period Notes of Sep 30 & Oct 1, 2010: - National Strategy for Aging - Supply of Medical Isotopes - The Human Papillomavirus (HPV)Vaccine, Cervarix, Manufactured by GlaxoSmithKline - Asbestos - Chrysotile - H1N1 Flu Vaccine Liability - Sanitary Practices for the 2010 Vancouver Olympic Games |
Disclosed in part |
| A-2009-01271 | Provide the document 2005-01-06 50330 adverse event, related to a clinical trial sponsored by Genpharm and conducted by Anapham. | Disclosed in part |
| A-2009-01276 | Provide the fax document by Ethica fax, dated December 19, 2005, regarding the SAE, related to a clinical trial sponsored by Genpharm and conducted by Anapham . | Disclosed in part |
| A-2009-01367 | Information regarding the product Novo-Olanzapine (DINs 02321343, 02321351, 02321378 and 02321386) by Novopharm Limited. | Disclosed in part |
| A-2009-01377 | All Health Canada inspection reports and related correspondence for the following radiopharmaceutical facility: Pharmalogic Pet Service of Montreal. | Disclosed in part |
| A-2009-01427 | Information regarding the product Biosil, NPN 80005878, by Preferred Nutrition Inc. | Disclosed in part |
| A-2009-01470 | Information sur le produit Ferroforte Injection 200 mg/mL, DIN 00857041 par Bimeda-MTC Animal Health Inc. | Disclosed in part |
| A-2010-00005 | All information regarding the extensive review of all available science to permit authorized broader use of caffeine as a food additive from cola-type beverages to all carbonated soft drinks, to allow adding synthetic caffeine to non-cola soft drinks in concentrations no higher than 150 parts per million (ppm). | All disclosed |
| A-2010-00096 | Information regarding the products Wm 2000; Essience Metabolic Plus, NPN 80013736 and Wm 2000 Green Tea, NPN 80015011. | Disclosed in part |
| A-2010-00125 | Information regarding the product Aquafresh Advance, NPN 02247197. | Disclosed in part |
| A-2010-00127 | Information regarding the product Sensodyne-F Mint Toothpaste; Sensodyne-F Whitening Plus Tarter Fighting Toothpaste, NPN 02243130. | Disclosed in part |
| A-2010-00155 | Information regarding the product Ulone Syr, DIN 01966294. | Disclosed in part |
| A-2010-00191 | Information regarding the medical devices Multi-Link Mini Vision Coronary Stent and Medtronic's Micro-Driver Coronary Stent by Abbott. | Disclosed in part |
| A-2010-00228 | All documentation regarding serious and unexpected adverse drug reactions that have occurred during clinical trials at Pharma Medica from 2002 to present (Jun 1, 2010). | Disclosed in part |
| A-2010-00291 | Information regarding the product Effient (prasugrel) by Eli Lilly Canada Inc. | Disclosed in part |
| A-2010-00313 | The total number of natural health product license applications processed by Health Canada. | All disclosed |
| A-2010-00435 | AERs. Report numbers: 000308747 and 000308831. | Disclosed in part |
| A-2010-00439 | Information regarding the products Effexor and Effexor XR (venlafaxine hydrochloride) by Wyeth Canada. | Disclosed in part |
| A-2010-00446 | Information regarding the product Probiotic Factors Powder, NPN 02240202 by Future Formulation Inc. | Disclosed in part |
| A-2010-00449 | Information regarding the product Probiotique, NPN 80011199 by Vitaminol Inc. | Disclosed in part |
| A-2010-00452 | Information regarding the product Adult Probiotic Formula, NPN 80011356 by Natural Vitamin Direct. | All disclosed |
| A-2010-00453 | Information regarding the product Chewable Probiotic Formula, NPN 80011464 by Vitaminol Inc. | Disclosed in part |
| A-2010-00468 | All flight kitchen food safety audits produced by Health Canada. Sep 1, 2009 to present (Jul 13, 2010). | Disclosed in part |
| A-2010-00578 | Copy of the Risk Management Plan (RMP) regarding the product VICTOZA (LIRAGLUTIDE), DINs 02351056 and 02351064 by NOVO NORDISK CANADA INC. | Disclosed in part |
| A-2010-00602 | Information regarding the product Mezavant (mesalamine), DIN 02297558 by Shire Canada Co. | Disclosed in part |
| A-2010-00616 | Information sur le produit Sculptra par Sanofi-aventis. | Disclosed in part |
| A-2010-00621 | Information regarding the medical devices LipoSonix by Medicis Pharmaceutical Corporation, the parent company of Medicis Technologies Corporation and Medicis Aesthetics Canada. | Disclosed in part |
| A-2010-00698 | Information regarding NPN 80018926. | Disclosed in part |
| A-2010-00712 | AER for the product Diamicron. Report number: 000312597. | Disclosed in part |
| A-2010-00713 | AER for the drug Perindopril. Report number: 000326748. | Disclosed in part |
| A-2010-00722 | AER for the product VASOTEC. Report number: 000313115. | Disclosed in part |
| A-2010-00773 | All information pertaining to a complaint lodged by Organon to the Pharmaceutical Advertising Advisory Board in 2005 regarding Yasmin. | Disclosed in part |
| A-2010-00789 | All information regarding legends and/or codes used for staffing actions for Health Canada Human Resource Management System, Advantage Desktop- GENPR033 | All disclosed |
| A-2010-00796 | All information submitted to Health Canada as part of the application process for Masai Marketing Canada Limited to receive a Medical Device Establishment licence. | All disclosed |
| A-2010-00811 | Product Monograph by Bayer Inc for the product Canesten 1% Topical cream (DIN 02150867). | All disclosed |
| A-2010-00819 | AER for the product ADALAT XL. Report number: 000349412. | Disclosed in part |
| A-2010-00826 | AERs for the product AVELOX. Report numbers: 000349287 and 000349375. | Disclosed in part |
| A-2010-00827 | Access to Information requests submitted to Health Canada for the period of October 2010. | Disclosed in part |
| A-2010-00828 | All Callups processed by this institution in the National Capital Region under the terms of any standing offer and/or supply arrangement for Temporary Help Services during the period of October 2010. | Disclosed in part |
| A-2010-00834 | Information regarding the product PHL-risedronate (risedronate sodium), DIN 02309874 by Pharmel Inc. | All exempted |
| A-2010-00839 | Information regarding the product Co-risedronate (risedronate sodium), DIN 02338718 by Cobalt Pharmaceuticals Company. | All exempted |
| A-2010-00840 | Information regarding the product Mylan-risedronate (risedronate sodium), DIN 02357984 by Mylan Pharmaceuticals. | All exempted |
| A-2010-00841 | Information regarding the product Dom-risedronate (risedronate sodium), DIN 02309831 by Dominion Pharmacal. | All exempted |
| A-2010-00865 | Copies of documents sent in response to Access to Information request A-2009-01303. | Disclosed in part |
| A-2010-00867 | Information regarding the product Avalide by SANOFI-AVENTIS CANADA INC. | Disclosed in part |
| A-2010-00879 | All records relating to Health Canada's collection and use of information from online publicly available data repositories and amore directly from Internet intermediaries. Between Jan 1, 2005 to Nov 16, 2010. | All disclosed |
| A-2010-00883 | Results of focus groups, consultation and other research on proposed updated cigarette-package warnings. | Disclosed in part |
| A-2010-00893 | Copy of the agreement under which Charles E (Chuck) Henry is working as Interim CIO at Health Canada. | Disclosed in part |
| A-2010-00906 | A list of completed Access to Information requests from Health Canada for August and September 2010. | Disclosed in part |
| A-2010-00918 | Information regarding the product Vitaros (Alprostadil) 220 micrograms/100 mg, DIN 02359413 by Nexmed USA Inc. | All exempted |
| A-2010-00919 | Information regarding the product Vitaros (Alprostadil) 3300 micrograms/100 mg, DIN 02359413 by Nexmed USA Inc. | All exempted |
| A-2010-00925 | Previously disclosed records for following Access to Information requests: A-2009-00815 - Regarding policy approaches other jurisdictions have undertaken or are currently pursuing, to reduce the amount of sodium in prepared foods. (January 2006 to September 2009). A-2010-00081 - Regarding clinical trials of drugs, biologics or medical devices that have been found to be non-compliant with Health Canada regulations governing clinical trials involving human subjects. (January 2004 to April 20, 2010). A-2010-00217 - Regarding pieces of children's jewellery found to contain cadmium. (2009 to March 2010). |
Disclosed in part |
| A-2010-00930 | Number of SAPs for Dacogen (Decitabine) for the month of November 2010. | All disclosed |
| A-2010-00931 | Number of SAPs for Fotolyn (Pralatrexate) for the month of November 2010. | All disclosed |
| A-2010-00932 | Number of SAPs for Prochymal (Remestemcel-L) for the month of November 2010. | All disclosed |
| A-2010-00933 | Number of SAPs for Targretin (Bexaretene) for the month of November 2010. | All disclosed |
| A-2010-00934 | Number of SAPs for Treanda (Bendamustine) for the month of November 2010. | All disclosed |
| A-2010-00935 | Number of SAPs for Carfilzomib for the month of November 2010. | All disclosed |
| A-2010-00 936 | Number of SAPs for Cabazitaxel (Jevtana) for the month of November 2010. | All disclosed |
| A-2010-00965 | All Callups processed by this institution in the National Capital Region under the terms of any Standing Offer and/or Supply Arrangement for Temporary Help Services during September 2010. | Disclosed in part |
